CIBC Private Wealth Group
SVA

CIBC Private Wealth Group’s Sinovac Biotech, Ltd SVA Stock Holding History

CIBC Private Wealth Group’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-24,600
Closed -$202K – 979
2019
Q4 		$202K Buy
+24,600
New +$202K ﹤0.01% 873

Other funds holding SVA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $4.34B AUM 19.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

CIBC Private Wealth Group's SVA Position: Q1 2020 in Review

CIBC Private Wealth Group sold out of Sinovac Biotech, Ltd (SVA) in Q1 2020, closing a stake of 24,600 shares — an estimated $202K sold.

CIBC Private Wealth Group first reported a position in SVA in Q4 2019 and held it in 1 quarter. The position peaked at $202K in Q4 2019. 24 funds tracked by Wall St. Rank hold SVA as of Q1 2020.

  • CIBC Private Wealth Group reported no remaining Sinovac Biotech, Ltd position as of Q1 2020 after selling out during the quarter.
  • CIBC Private Wealth Group sold 24,600 Sinovac Biotech, Ltd shares in Q1 2020, an estimated $202K.
  • CIBC Private Wealth Group first reported a position in Sinovac Biotech, Ltd in Q4 2019 and held it in 1 quarter.
  • CIBC Private Wealth Group's Sinovac Biotech, Ltd position peaked at $202K in Q4 2019.
  • 24 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2020.

Based on CIBC Private Wealth Group's 13F filing for Q1 2020, filed 15 May 2020.